Clinical data demonstrates high uptake of GRPR-targeting antagonistic peptides in patients with estrogen receptor positive breast cancer both in primary lesions, lymph node and bone metastases (Chernov et al. 2023; Nock et al. 2021; Zang et al. 2018). The gene discussed is ESR1; the disease is breast carcinoma.